Efficacy of roflumilast in the COPD frequent exacerbator phenotype.

@article{Wedzicha2013EfficacyOR,
  title={Efficacy of roflumilast in the COPD frequent exacerbator phenotype.},
  author={Jadwiga A Wedzicha and Klaus Friedrich Rabe and Fernando J Martinez and Dirk Bredenbroeker and Manja Brose and U M Goehring and Peter M. A. Calverley},
  journal={Chest},
  year={2013},
  volume={143 5},
  pages={1302-1311}
}
BACKGROUND COPD exacerbations are associated with increased morbidity and mortality and can accelerate disease progression. The best predictor of future exacerbations is a history of previous exacerbations, which helps identify a frequent exacerbator phenotype. This post hoc analysis evaluated the effect of roflumilast, a drug known to reduce the COPD exacerbation rate, on exacerbation status. METHODS Pooled data from two 1-year, placebo-controlled, roflumilast (500 μg once daily) studies in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

Archivum Immunologiae et Therapiae Experimentalis • 2015
View 14 Excerpts
Highly Influenced

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study

International journal of chronic obstructive pulmonary disease • 2017

Roflumilast: a review of its use in the treatment of COPD

International journal of chronic obstructive pulmonary disease • 2016
View 2 Excerpts

COPD: it is time to change!

International journal of chronic obstructive pulmonary disease • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…